1202 Hay Street
West Perth, WA 6005
61 8 6382 3390
Industry: Drug Manufacturers—Specialty & Generic
|Mr. Roby Reuven Zomer||Co-Founder, CEO, MD & Exec. Director||484.63k||N/A||1980|
|Mr. Tom Cairns||Chief Accounting Officer||N/A||N/A||N/A|
|Ms. Yifat Steuer||Deputy CEO & COO||N/A||N/A||N/A|
|Ms. Nicole Ann Godresse||Global Chief Sales Officer||N/A||N/A||N/A|
|Mr. Amir Polak||Chief Pharmaceutical Devel. Officer||N/A||N/A||N/A|
|Ms. Sabina Suljakovic||Head of the Quality Assurance Department||N/A||N/A||N/A|
|Dr. Nadya Lisovoder||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Sasha Friedman||Deputy CEO||N/A||N/A||N/A|
|Yair Tal||Chief Information Security Officer||N/A||N/A||N/A|
|Mr. Robert Clements||Chief Commercial Officer||N/A||N/A||N/A|
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.
MGC Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.